CC
IOBT

Cannell Capital’s IO Biotech IOBT Stock Holding History

Cannell Capital’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,594
Closed -$23.6K – 76
2023
Q1 		$23.6K Hold
12,594
– – ﹤0.01% 83
2022
Q4 		$29K Hold
12,594
– – 0.01% 82
2022
Q3 		$34K Buy
12,594
+10,402
+475% +$38.6K 0.01% 86
2022
Q2 		$10K Buy
+2,192
New +$13.4K ﹤0.01% 85

Other funds holding IOBT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AAM
Aureus Asset Management Boston, Massachusetts $1.65B AUM 26.32% 1-Year Est. Return

Cannell Capital's IOBT Position: Q2 2023 in Review

Cannell Capital sold out of IO Biotech (IOBT) in Q2 2023, closing a stake of 12,594 shares — an estimated $23.6K sold.

Cannell Capital first reported a position in IOBT in Q2 2022 and held it in 4 quarters. The position peaked at $34K in Q3 2022. 15 funds tracked by Wall St. Rank hold IOBT as of Q2 2023.

  • Cannell Capital reported no remaining IO Biotech position as of Q2 2023 after selling out during the quarter.
  • Cannell Capital sold 12,594 IO Biotech shares in Q2 2023, an estimated $23.6K.
  • Cannell Capital first reported a position in IO Biotech in Q2 2022 and held it in 4 quarters.
  • Cannell Capital's IO Biotech position peaked at $34K in Q3 2022.
  • 15 funds tracked by Wall St. Rank held IO Biotech as of Q2 2023.

Based on Cannell Capital's 13F filing for Q2 2023, filed 14 Aug 2023.